Jefferies Financial Group Inc. raised its holdings in Embecta Corp. (NASDAQ:EMBC - Free Report) by 40.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,884,875 shares of the company's stock after purchasing an additional 542,162 shares during the quarter. Jefferies Financial Group Inc. owned 3.22% of Embecta worth $26,596,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently made changes to their positions in the business. Laurel Wealth Advisors LLC boosted its holdings in shares of Embecta by 754.3% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,871 shares of the company's stock worth $193,000 after buying an additional 1,652 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Embecta by 542.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company's stock worth $71,000 after buying an additional 6,224 shares during the last quarter. Neuberger Berman Group LLC purchased a new stake in Embecta during the third quarter worth about $143,000. Pacer Advisors Inc. bought a new stake in Embecta in the third quarter worth about $156,000. Finally, Summit Global Investments bought a new stake in Embecta in the third quarter worth about $161,000. 93.83% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research analysts have recently weighed in on EMBC shares. BTIG Research reissued a "buy" rating and set a $25.00 target price on shares of Embecta in a research report on Friday, February 6th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Embecta in a report on Wednesday, January 21st. Finally, Wall Street Zen upgraded Embecta from a "buy" rating to a "strong-buy" rating in a research note on Saturday. One equities research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $18.50.
View Our Latest Analysis on Embecta
Embecta Stock Performance
Shares of Embecta stock opened at $9.07 on Monday. Embecta Corp. has a 52-week low of $9.06 and a 52-week high of $15.55. The stock's 50-day simple moving average is $11.08 and its 200 day simple moving average is $12.74. The stock has a market capitalization of $537.13 million, a P/E ratio of 3.83 and a beta of 1.10.
Embecta (NASDAQ:EMBC - Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.67 by $0.04. The business had revenue of $261.20 million for the quarter, compared to the consensus estimate of $258.07 million. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The company's revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.65 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. Equities research analysts forecast that Embecta Corp. will post 2.85 EPS for the current fiscal year.
Embecta Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 17th. Investors of record on Friday, February 27th will be paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date is Friday, February 27th. Embecta's dividend payout ratio is presently 25.32%.
Embecta Profile
(
Free Report)
Embecta Corp NASDAQ: EMBC is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.
The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.
Featured Articles
Want to see what other hedge funds are holding EMBC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Embecta Corp. (NASDAQ:EMBC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Embecta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Embecta wasn't on the list.
While Embecta currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.